Page 7 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. In this randomized controlled trial, semaglutide was more effective in reducing heart failure-related symptoms and physical limitations in patients with obesity-related heart failure and type 2 diabetes mellitus (T2DM) than placebo. 2. Patients with obesity-related heart failure and T2DM exhibited greater weight loss with semaglutide than placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.

Safia Chatur, MD, discusses the results of a PARADIGM-HF analysis at ACC.24 examining the effects of ARNI use across the updated 2024 KDIGO Risk Classifications.

Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.